Biotech company makes deal with Bayer division

May 18, 2005 — The biological products division of Bayer HealthCare LLC and Asklepios Biopharmaceutical Inc. (AskBio) entered into an early-stage research and collaboration agreement to evaluate gene therapy for the treatment of hemophilia B. The collaboration could lead to a joint development and commercialization agreement for the novel gene therapy treatment for hemophilia B.

AskBio, a private development-stage biotechnology company, is conducting preclinical testing of a synthetically designed biological nanoparticle gene therapy, containing the factor IX gene for the treatment of hemophilia B. Biological nanoparticles are designed to deliver the factor IX gene into patient muscle cells and produce sustained expression of factor IX. Factor IX levels in excess of 3 percent of normal levels are expected to substantially reduce spontaneous bleeding episodes. Bayer HealthCare AG is a subsidiary of Bayer AG.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.